Marksans Pharma [MARKSANS] vs Granules India [GRANULES] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Marksans Pharma Ltd. wins in 11 metrics, Granules India Ltd. wins in 9 metrics, with 0 ties. Marksans Pharma Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Marksans Pharma Ltd. | Granules India Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 23.96 | 29.90 | Marksans Pharma Ltd. |
| Price-to-Book Ratio | 3.20 | 4.10 | Marksans Pharma Ltd. |
| Debt-to-Equity Ratio | 12.24 | 45.37 | Marksans Pharma Ltd. |
| PEG Ratio | 2.91 | 1.08 | Granules India Ltd. |
| EV/EBITDA | 17.15 | 16.93 | Granules India Ltd. |
| Profit Margin (TTM) | 12.85% | 10.71% | Marksans Pharma Ltd. |
| Operating Margin (TTM) | 18.08% | 16.90% | Marksans Pharma Ltd. |
| EBITDA Margin (TTM) | 18.08% | 16.90% | Marksans Pharma Ltd. |
| Return on Equity | 15.29% | 13.50% | Marksans Pharma Ltd. |
| Return on Assets (TTM) | 11.75% | 8.02% | Marksans Pharma Ltd. |
| Free Cash Flow (TTM) | $337.45M | $2.95B | Granules India Ltd. |
| Dividend Yield | 0.62% | 0.30% | Marksans Pharma Ltd. |
| 1-Year Return | -2.65% | 50.46% | Granules India Ltd. |
| Price-to-Sales Ratio (TTM) | 3.07 | 3.27 | Marksans Pharma Ltd. |
| Enterprise Value | $84.41B | $173.92B | Granules India Ltd. |
| EV/Revenue Ratio | 3.01 | 3.42 | Marksans Pharma Ltd. |
| Gross Profit Margin (TTM) | 58.08% | 63.60% | Granules India Ltd. |
| Revenue per Share (TTM) | $62 | $210 | Granules India Ltd. |
| Earnings per Share (Diluted) | $7.94 | $22.50 | Granules India Ltd. |
| Beta (Stock Volatility) | 1.03 | -0.08 | Granules India Ltd. |
Marksans Pharma Ltd. vs Granules India Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Marksans Pharma Ltd. | -1.03% | 5.80% | 20.40% | 51.59% | 31.03% | 38.86% |
| Granules India Ltd. | -2.34% | -2.33% | 1.67% | 32.01% | 30.95% | 20.88% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Marksans Pharma Ltd. | -2.65% | 181.04% | 197.61% | 488.28% | 10,872.61% | 2,742.00% |
| Granules India Ltd. | 50.46% | 162.44% | 146.61% | 452.60% | 8,639.45% | 8,917.06% |
Performance & Financial Health Analysis: Marksans Pharma Ltd. vs Granules India Ltd.
| Metric | MARKSANS | GRANULES |
|---|---|---|
| Market Information | ||
| Market Cap | ₹86.20B | ₹170.22B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 1,036,499 | 1,262,375 |
| 90 Day Avg. Volume | 832,265 | 1,054,744 |
| Last Close | ₹249.76 | ₹748.50 |
| 52 Week Range | ₹155.00 - ₹266.60 | ₹432.60 - ₹804.30 |
| % from 52W High | -6.32% | -6.94% |
| All-Time High | ₹358.70 (Dec 02, 2024) | ₹804.30 (May 29, 2026) |
| % from All-Time High | -30.37% | -6.94% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.22% |
| Quarterly Earnings Growth | 0.08% | 0.28% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.11% |
| Operating Margin (TTM) | 0.18% | 0.17% |
| Return on Equity (TTM) | 0.15% | 0.14% |
| Debt to Equity (MRQ) | 12.24 | 45.37 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹59.37 | ₹164.06 |
| Cash per Share (MRQ) | ₹14.74 | ₹25.51 |
| Operating Cash Flow (TTM) | ₹2.42B | ₹7.56B |
| Levered Free Cash Flow (TTM) | ₹3.81B | ₹5.02B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.62% | 0.30% |
| Last 12-Month Dividend | ₹1.40 | ₹1.50 |
Valuation & Enterprise Metrics Analysis: Marksans Pharma Ltd. vs Granules India Ltd.
| Metric | MARKSANS (Apr 26, 2026) | GRANULES (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 23.96 | 29.90 |
| Forward P/E | 17.29 | 22.35 |
| PEG Ratio | 2.91 | 1.08 |
| Price to Sales (TTM) | 3.07 | 3.27 |
| Price to Book (MRQ) | 3.20 | 4.10 |
| Market Capitalization | ||
| Market Capitalization | ₹86.20B | ₹170.22B |
| Enterprise Value | ₹84.41B | ₹173.92B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.01 | 3.42 |
| Enterprise to EBITDA | 17.15 | 16.93 |
| Risk & Other Metrics | ||
| Beta | 1.03 | -0.08 |
| Book Value per Share (MRQ) | ₹59.37 | ₹164.06 |
Financial Statements Comparison: Marksans Pharma Ltd. vs Granules India Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | MARKSANS (2025) | GRANULES (2025) |
|---|---|---|
| Revenue/Sales | 26.14B | 44.56B |
| Cost of Goods Sold | 12.29B | 18.34B |
| COGS % of Revenue | 47.0% | 41.1% |
| Gross Profit | 13.85B | 26.22B |
| Gross Margin | 53.0% | 58.9% |
| Research & Development | N/A | 2.38B |
| Operating Income (EBIT) | 4.56B | 7.29B |
| Operating Margin | 17.4% | 16.4% |
| EBITDA | 6.06B | 9.25B |
| EBITDA Margin | 23.2% | 20.8% |
| Pre-Tax Income | 5.04B | 6.60B |
| Pre-Tax Income % of Revenue | 19.3% | 14.8% |
| Income Tax | 1.21B | 1.59B |
| Income Tax % of Revenue | 4.6% | 3.6% |
| Net Income (Profit) | 3.83B | 5.02B |
| Profit Margin | 14.6% | 11.3% |
Balance Sheet & Liquidity Metrics
| Metric | MARKSANS (2025) | GRANULES (2025) |
|---|---|---|
| Cash & Equivalents | 4.96B | 4.66B |
| Total Current Assets | 22.04B | 31.15B |
| Total Current Assets % of Revenue | 84.3% | 69.9% |
| Total Current Liabilities | 4.77B | 20.03B |
| Total Current Liabilities % of Revenue | 18.3% | 45.0% |
| Long-Term Debt | 2.63B | 4.71B |
| Long-Term Debt % of Revenue | 10.1% | 10.6% |
| Total Shareholders Equity | 24.89B | 37.16B |
| Retained Earnings | 14.22B | 30.59B |
| Retained Earnings % of Revenue | 54.4% | 68.7% |
| Property, Plant & Equipment | 185.74M | 719.13M |
Cash Flow Statement Comparison
| Metric | MARKSANS (2025) | GRANULES (2025) |
|---|---|---|
| Operating Cash Flow | 2.42B | 7.56B |
| Operating Cash Flow % of Revenue | 9.3% | 17.0% |
| Capital Expenditures | -1.72B | -5.70B |
| Free Cash Flow | 337.45M | 2.95B |
| FCF Margin | 1.3% | 6.6% |
| Debt Repayment | -60.06M | -23.41B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MARKSANS | GRANULES |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 453.16M | 247.80M |
| Float Shares | 214.30M | 147.11M |
| % Held by Insiders | 44.06% | 39.31% |
| % Held by Institutions | 18.21% | 23.27% |
| % Held by Public | 37.73% | 37.42% |
Dividend Analysis & Yield Comparison: Marksans Pharma Ltd. vs Granules India Ltd.
| Metric | MARKSANS | GRANULES |
|---|---|---|
| Last 12-Month Dividend | ₹1.40 | ₹1.50 |
| Last 12-Month Dividend Yield | 0.62% | 0.30% |
| 3-Year Avg Annual Dividend | ₹0.72 | ₹1.50 |
| 3-Year Avg Dividend Yield | 0.40% | 0.33% |
| 3-Year Total Dividends | ₹2.15 | ₹4.50 |
| Ex-Dividend Date | Aug 01, 2025 | Jul 31, 2025 |